Clinical Trials in Georgia

Showing 6661-6680 of 19,050 trials

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Amneal Pharmaceuticals, LLC240 participantsStarted Apr 2024

Bakersfield, California, United States • Newport Beach, California, United States • Morrow, Georgia, United States +1 more locations

RECRUITINGPhase 165 miles

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

NCT06271252

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasms+11 more

OriCell Therapeutics Co., Ltd.81 participantsStarted Apr 2024

Atlanta, Georgia, United States

COMPLETEDPhase 2164 miles

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00042003

To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.

Chronic Myelogenous Leukemia

Astex Pharmaceuticals, Inc.40 participantsStarted Jul 2002

Duarte, California, United States • Escondido, California, United States • Los Angeles, California, United States +5 more locations

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Find Trials by Condition in Georgia

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma

Endpoint Determination Study Protocol

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Hypertrophic Cardiomyopathy Federated Learning Implementation Platform

Comparative Effectiveness of FITs With Colonoscopy

Evaluation of the Tympanostomy Tube Delivery System

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Study of RBI-4000 in Healthy Participants

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)